【摘要】：目的采用Meta分析比較全腦放療(WBRT)聯(lián)合靶向藥物與單用WBRT在非小細胞肺癌(NSCLC)腦轉移瘤患者治療中的療效和安全性。方法計算機檢索Pubmed、Embase、中國知網、萬方數據庫中有關WBRT聯(lián)合靶向藥物治療NSCLC腦轉移的文獻,檢索時間均從建庫至2016年5月。通過紐卡斯爾-渥太華量表(NOS)對文獻進行質量評價,采用優(yōu)勢比(OR)及其95%可信區(qū)間合并效應量,采用Rev Man5.2軟件進行數據分析。結果最終納入15篇研究文獻,共計1 084例患者。結果顯示:聯(lián)合治療組疾病控制率(OR:3.09,95%CI 2.11~4.54,P0.00001)、1年生存率(OR:2.55,95%CI 1.84~3.54,P0.00001)均高于單純放療組,差異具有明顯統(tǒng)計學意義;安全性方面,聯(lián)合治療組皮疹發(fā)生率高于單純放療組(OR:9.10,95%CI 2.89~28.66,P=0.0002),但均屬于Ⅰ~Ⅱ度不良反應,經對癥處理后可緩解,其余不良反應如腹瀉、惡心嘔吐、乏力、骨髓抑制、呼吸困難兩組比較均無統(tǒng)計學意義(P0.05)。結論WBRT聯(lián)合靶向藥物治療NSCLC腦轉移瘤明顯優(yōu)于單純WBRT放療,不良反應亦無明顯增加。
[Abstract]:Objective to compare the efficacy and safety of global brain radiotherapy (WBRT) combined with targeted drugs and WBRT alone in the treatment of (NSCLC) brain metastases from non-small cell lung cancer (NSCLC) by Meta analysis. Methods the literatures about the treatment of brain metastasis of NSCLC with WBRT combined with targeted drugs in Wanfang database were searched by computer. The retrieval time was from the establishment of the database to May 2016. The quality of literature was evaluated by Newcastle Ottawa scale (NOS). The dominance ratio (OR) and its 95% confidence interval (CI) combined effect were used to analyze the data by Rev Man5.2 software. Results A total of 1 084 patients were included in 15 articles. The results showed that the disease control rate (OR:3.09,95%CI 2.114.54) and the 1-year survival rate (OR:2.55,95%CI 1.84 + 3.54% P0.00001) in the combined treatment group were significantly higher than those in the radiotherapy alone group (P 0.00001), and the difference was statistically significant. The incidence of skin rash in the combined treatment group was higher than that in the radiotherapy alone group (OR:9.10,95%CI 2.89 ~ 28.66 P0. 0002), but all of them belonged to 鈪，

本文編號：2238012